Ionis Pharmaceuticals (IONS) concentration risks

The company's disclosed concentration profile centers on two collaboration-level dependencies, each carrying a moderate disclosed size. The company depends on its collaboration with Biogen for the development and commercialization of SPINRAZA and QALSODY, and separately depends on its collaboration with AstraZeneca for the joint development and commercialization of WAINUA. Both are dependency exposures: the company's ability to generate revenue from these assets is contingent on the continued commitment, commercial execution, and regulatory standing of its partners rather than on the company's own direct commercial operations. The two dependencies are distinct at the partner level — Biogen and AstraZeneca are separate counterparties with independent balance sheets, pipelines, and commercial strategies — which provides some diversification compared to reliance on a single collaboration. However, both exposures are moderate by disclosed size and both are partnership-driven, meaning that a strategic reprioritization, a commercial setback, or a change in the financial posture of either partner could reduce royalty and milestone income without any change in the underlying science or the company's own performance. Taken together, the concentration profile is defined by counterparty dependency rather than product or geographic concentration. The key variables to monitor are the commercial trajectories of SPINRAZA, QALSODY, and WAINUA in their respective markets, and the durability of the collaborative agreements that govern revenue-sharing for each product.

For the engine’s reasoning on IONS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.